Supraspinatus Tendinopathy Clinical Trial
Official title:
Electrolysis Percutaneous Therapeutic (EPTE) for the Management of Supraspinatus Tendinopathy
Therapeutic management of supraspinatus tendinopathy is conflicting. There is evidence that eccentric exercise protocols can be effective for this condition. The inclusion of other therapeutic modalities could help to the management of these patients. A new therapeutic approach, called Electrolysis Percutaneous Therapeutic (EPTE) has been clinically developed. The objective of this randomized clinical trial is to determine the effectiveness of the inclusion of EPTE into a eccentric exercise protocol for the management of patients with unilateral supraspinatus tendinopathy
Status | Completed |
Enrollment | 36 |
Est. completion date | December 2014 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Unilateral supraspinatus tendinopathy - Shoulder pain from at least 3 months - Shoulder pain of more than 4 points on a NPRS - Positive findings of supraspinatus tendinopathy on MRI Exclusion Criteria: - bilateral shoulder symptoms - younger than 18 or older than 65 years - history of shoulder fractures or dislocation - cervical radiculopathy - previous interventions with steroid injections - fibromyalgia syndrome - previous history of shoulder or neck surgery - any type of intervention for the neck-shoulder area during the previous year |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Spain | Universidad Rey Juan Carlos | Alcorcon | Madrid |
Lead Sponsor | Collaborator |
---|---|
Universidad Rey Juan Carlos |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in pain intensity before and after the intervention | A 10-point Numerical Pain Rating Scale (NPRS; 0: no pain, 10: maximum pain) will be used to assess the patients' current level of shoulder pain, and the worst and lowest level of pain experienced in the preceding week in the shoulder area. | Baseline, after 2 weeks of treatment and one week after the last session | Yes |
Secondary | Changes in disability before and after the intervention | The Disabilities of the Arm, Shoulder and Hand (DASH) will be used to determine the disability induced by shoulder pain | Baseline, after 2 weeks of treatment and one week after the last session | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03942640 -
Perineural Injection and Supraspinatus Tendenopathy
|
N/A |